Trending...
- Generic Trade Marks 15 Years of Leveling the Trading Field for all Futures Traders
- READY FOR NEW BUILDS – Pond & Waterfall Construction Season Starts Now!
- Levata Acquires Logiscenter to Accelerate Growth in Enterprise IT and Data Capture Solutions
CHICAGO, June 22, 2025 ~ A new dual agonist, CagriSema, has shown promising results in improving weight loss for patients with and without type 2 diabetes who have overweight or obesity. The findings were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and simultaneously published in the New England Journal of Medicine.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
According to recent studies, nearly 90% of adults in the United States who have diabetes also have overweight or obesity. This highlights the strong connection between excess weight and the development or progression of type 2 diabetes. While there have been advancements in treatment options for obesity and type 2 diabetes with glucagon-like peptide-1 (GLP-1) receptor agonists, there is still a need for therapies that can address both weight and glucose management simultaneously.
CagriSema, a dual agonist that targets both appetite control and glucose regulation, aims to fill this gap. The drug is a once-weekly combination of semaglutide and cagrilintide, two weight-loss medications.
More on illi News
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- Chicago: Mayor Johnson, City Officials Honor 1995 Heat Wave Victims, Forgotten WWII Hero Emilio Aguirre with Full Military Funeral Honors
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Disposable Vape Ban Spurs Hayati Innovation
- Prolific Hollywood "Unknown Actor" Leads 11 Day SoCal, Hands-On, Performer Employment Securing Residency that Shows Others How to Get More Work
The effectiveness and safety of CagriSema were evaluated in two phase 3 studies known as REDEFINE 1 and REDEFINE 2. REDEFINE 1 included 3,400 adults without diabetes but with at least one weight-related health condition such as high blood pressure or heart disease. Participants were randomly assigned to receive CagriSema, semaglutide, cagrilintide, or placebo. On the other hand, REDEFINE 2 enrolled 1,200 adults with type 2 diabetes who received either CagriSema or placebo.
Both studies met their goals by demonstrating significant weight loss with once-weekly CagriSema compared to placebo. In REDEFINE 1, participants lost an average of 20.4% of their body weight at week 68 with CagriSema compared to only 3% with placebo. When considering full treatment adherence, weight loss with CagriSema increased to 22.7%, and 40.4% of participants achieved at least 25% weight loss. Similarly, in REDEFINE 2, participants lost an average of 13.7% of their body weight at week 68 with CagriSema compared to only 3.4% with placebo. When accounting for all study participants who adhered to treatment, weight loss with CagriSema rose to 15.7%, while only 3.1% was seen in the placebo group.
More on illi News
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
- Agreement to Deliver Thin-Film Solar Technology to Space Solar Array Provider, NASA Collaborative Agreement for Orbital Applications in Power Beaming
- Iterators LLC Honored with IST82 State Award for Accessibility in Massachusetts
- Samyang Corporation Unveils 'AI-Based Standardized Sugar Reduction Solution' at US Food Technology Expo
- Josh & Heidi Share Upcoming "Spreading the Good BUZZ" Podcast Guests, Select Top Five Elopement Locations as Their Instagram Presence Grows Globally
The safety profile of CagriSema was consistent with other GLP-1 receptor agonists, with mild-to-moderate gastrointestinal issues being the most common side effects.
Professor Melanie Davies from the University of Leicester commented on the findings, stating that they represent a significant step forward in expanding treatment options for people living with obesity and type 2 diabetes. She emphasized the importance of developing therapies that not only promote meaningful weight loss but also improve glucose control, giving patients more tools to manage their health effectively.
The researchers involved in this study note that it is part of a larger REDEFINE program that aims to evaluate the effectiveness of CagriSema across different populations and inform future regulatory submissions.
The findings were presented by Professor Davies and Dr. Timothy Garvey at a symposium during the ADA's Scientific Sessions on June 22nd at 8:00 a.m CT. The presentation focused on the efficacy and safety of CagriSema in adults with overweight or obesity based on data from REDEFINE 1 and REDEFINE 2 clinical trials.
Filed Under: Business
0 Comments
Latest on illi News
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- AI Maturity Emerges as Key Driver of ROI, New Protiviti Study Finds
- Premier Custom Hardwood Flooring Launches New Website to Better Serve Homeowners and Businesses in the NW Chicago Suburbs
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- WIOA-Funded Seats Still Available for Summer Product-Owner Training
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Psychedelics for Vets? CCHR Cites History of Exploitation and Failed Science
- Entyre Solutions Launches to Support Senior Living Operators
- Jungbunzlauer Launches New TayaGel® LA at IFT First 2025, strengthening its texturants portfolio USA - English USA - English USA - Français Japan - Japanese USA - Deutsch
- GreenPal Empowers Lawn Care Pros Leveraging AI, Surpasses 5 Million Transactions
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Eliza Nevius Reimagines a Classic with a Dark, Witty Twist in The Key to Wonderland
- Naperville Police Initiate Death Investigation
- The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
- Mayor Johnson Appoints Era Patterson As Executive Director Of The Chicago Office Of Public Safety Administration